Search

Introduction: The antioxidant effects of vitamins may attenuate the oxidative stress on organs imposed by ischemia–reperfusion injury during the process of organ transplantation from brain-dead donors. Circulating levels of vitamins A, C, and E-α in donors after brain death and their relationships to donor demographics, management, organ utilization, and recipient outcomes are largely unknown. Methods: An observational, prospective, cohort study of 84 consecutive brain-dead organ donors managed at a single organ procurement recovery center was conducted. Vitamin levels were drawn immediately prior to procurement. Results: Levels of serum vitamins A and E-α and plasma vitamin C were below normal in 80%, 85%, and 92% of donors and deficient in 40%, 62%, and 63%, respectively. Vitamin C deficiency was associated with a longer time between death and specimen collection (P =.004). Death from head trauma and stroke were associated with lower levels of vitamin A than from anoxic causes (P =.003) and smokers had greater vitamin C deficiency (P =.03). During donor management, vitamin C deficiency was associated with longer vasopressor support (P =.03) and normal levels of vitamin E-α were associated with reaching a lower alanine transferase compared to those with subnormal levels (P <.05). Donors deficient in vitamin E-α were less likely to have a liver recovered for transplantation (P =.005). Vitamin levels were not associated with the recipient outcomes examined. Conclusion: Circulating vitamins A, C, and E-α is profoundly low in brain-dead organ donors, associated with relevant demographic features of the donor, and may influence donor management and organ utilization. [ABSTRACT FROM AUTHOR]

Eighty percent of brain‐dead (BD) organ donors develop hypotension and are frequently hypovolemic. Fluid resuscitation in a BD donor is controversial. We have previously published our 4‐h goal‐directed stroke volume (SV)‐based fluid resuscitation protocol which significantly decreased time on vasopressors and increased transplanting four or more organs. The SV was measured by pulse‐contour analysis (PCA) or an esophageal doppler monitor, both of which are invasive. Thoracic bioreactance (BR) is a non‐invasive portable technology that measures SV but has not been studied in BD donors. We performed a randomized prospective comparative study of BR versus PCA technology in our fluid resuscitation protocol in BD donors. Eighty‐four donors (53.1%) were randomized to BR and 74 donors to PCA (46.8%). The two groups were well matched based on 24 demographic, social, and initial laboratory factors, without any significant differences between them. There was no difference in the intravenous fluid infused over the 4‐h study period [BR 2271 ± 823 vs. PCA 2230 ± 962 mL; p =.77]. There was no difference in the time to wean off vasopressors [BR 108.8 ± 61.8 vs. PCA 150.0 ± 68 min p =.07], nor in the number of donors off vasopressors at the end of the protocol [BR 16 (28.6%) vs. PCA 15 (29.4%); p =.92]. There was no difference in the total number of organs transplanted per donor [BR 3.25 ± 1.77 vs. PCA 3.22 ± 1.75; p =.90], nor in any individual organ transplanted. BR was equivalent to PCA in clinical outcomes and provides a simple, non‐invasive, portable technology to monitor fluid resuscitation in organ donors. [ABSTRACT FROM AUTHOR]

The authors acknowledge the importance of precise language regarding organ donors in response to a comment. It mentions express their commitment to honoring the generous gift of life provided by organ donors and emphasize their focus on maximizing the value of organ donation. It authors also respond to concerns about potential biases in their thyroid hormone supplementation trial.

Drug overdoses have tripled in the United States over the last two decades. With the increasing demand for donor organs, one potential consequence of the opioid epidemic may be an increase in suitable donor organs. Unfortunately, organs from donors dying of drug overdose have poorer utilization rates than other groups of brain‐dead donors, largely due to physician and recipient concerns about viral disease transmission. During the study period of 2011 to 2016, drug overdose donors (DODs) account for an increasingly greater proportion of the national donor pool. We show that a novel model of donor care, known as specialized donor care facility (SDCF), is associated with an increase in organ utilization from DODs compared to the conventional model of hospital‐based donor care. This is likely related to the close relationship of the SDCF with the transplant centers, leading to improved communication and highly efficient donor care. [ABSTRACT FROM AUTHOR]